AR066266A1 - DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR - Google Patents

DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR

Info

Publication number
AR066266A1
AR066266A1 ARP080101710A ARP080101710A AR066266A1 AR 066266 A1 AR066266 A1 AR 066266A1 AR P080101710 A ARP080101710 A AR P080101710A AR P080101710 A ARP080101710 A AR P080101710A AR 066266 A1 AR066266 A1 AR 066266A1
Authority
AR
Argentina
Prior art keywords
6alkyl
6alkoxy
acid
6haloalkyl
phenyl
Prior art date
Application number
ARP080101710A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39876087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066266(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR066266A1 publication Critical patent/AR066266A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP080101710A 2007-04-23 2008-04-23 DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR AR066266A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91331207P 2007-04-23 2007-04-23

Publications (1)

Publication Number Publication Date
AR066266A1 true AR066266A1 (es) 2009-08-05

Family

ID=39876087

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101710A AR066266A1 (es) 2007-04-23 2008-04-23 DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR

Country Status (23)

Country Link
US (2) US8143408B2 (enExample)
EP (1) EP2158198B1 (enExample)
JP (1) JP2010525056A (enExample)
KR (1) KR20100015827A (enExample)
CN (1) CN101687860B (enExample)
AR (1) AR066266A1 (enExample)
AU (1) AU2008241610B2 (enExample)
BR (1) BRPI0810354A2 (enExample)
CA (1) CA2685141A1 (enExample)
CL (1) CL2008001170A1 (enExample)
CO (1) CO6251361A2 (enExample)
EC (1) ECSP099706A (enExample)
IL (1) IL201309A0 (enExample)
MX (1) MX2009011364A (enExample)
MY (1) MY146662A (enExample)
NZ (1) NZ581353A (enExample)
PE (1) PE20090727A1 (enExample)
RU (1) RU2460730C2 (enExample)
SA (1) SA08290245B1 (enExample)
TW (1) TW200848037A (enExample)
UY (1) UY31046A1 (enExample)
WO (1) WO2008130320A2 (enExample)
ZA (1) ZA200907137B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2942346B1 (en) 2009-02-17 2020-05-06 Syntrix Biosystems, Inc. Pyridinecarboxamides as cxcr2 modulators
KR20120091240A (ko) * 2009-10-26 2012-08-17 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물의 합성 및 정제 방법
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
US20190192510A1 (en) 2010-02-01 2019-06-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
US8779149B2 (en) 2010-08-23 2014-07-15 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
WO2012039657A1 (en) * 2010-09-22 2012-03-29 Astrazeneca Ab Novel chromane compound for the treatment of pain disorders
CN102408385B (zh) * 2011-06-20 2014-06-18 雅本化学股份有限公司 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102408386B (zh) * 2011-07-27 2014-05-07 雅本化学股份有限公司 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102603659B (zh) * 2012-03-01 2014-03-26 雅本化学股份有限公司 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法
NZ710111A (en) * 2013-01-31 2020-08-28 Vertex Pharma Quinoline and quinoxaline amides as modulators of sodium channels
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
CA2938719A1 (en) * 2014-02-06 2015-08-13 Abbvie, Inc. 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
MY194015A (en) 2015-11-13 2022-11-08 Daewoong Pharmaceutical Co Ltd Sodium channel blocker
CN105541774B (zh) * 2016-01-13 2018-06-15 华中师范大学 3,4-二氢香豆素类化合物及其制备方法和用途
UA125800C2 (uk) * 2017-06-30 2022-06-08 Баєр Енімал Хелс Гмбх Похідні азахіноліну
MD3740481T3 (ro) 2018-01-19 2025-06-30 Cytokinetics Inc Analogi de dihidrobenzofuran și inden în calitate de inhibitori ai sarcomerului cardiac
CA3093189A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
BR112021001608A2 (pt) 2018-09-10 2021-04-27 Kaken Pharmaceutical Co., Ltd. derivado de amida heteroaromático inovador e medicamento contendo o mesmo
WO2020234103A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification and use of kras inhibitors
JP2024508526A (ja) 2021-03-04 2024-02-27 サイトキネティックス, インコーポレイテッド 心筋サルコメア阻害剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
WO1994012493A1 (en) * 1992-11-25 1994-06-09 Sandoz, Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals
JPH0827153A (ja) * 1994-07-12 1996-01-30 Nippon Kayaku Co Ltd アザクロマン誘導体及びその用途
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
GB9713804D0 (en) * 1997-06-30 1997-09-03 Novo Nordisk As Particulate polymeric materials and their use
JPH1135569A (ja) 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd ポリフェノール化合物及びこれを含有する医薬
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
KR20060073930A (ko) * 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
EP1877385A1 (en) * 2005-05-04 2008-01-16 Vertex Pharmaceuticals Incorporated Pyrimidines and pyrazines useful as modulators of ion channels
CN101490002A (zh) * 2006-07-12 2009-07-22 阿斯利康(瑞典)有限公司 作为止痛剂的3-氧代异二氢吲哚-1-甲酰胺衍生物
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم

Also Published As

Publication number Publication date
ZA200907137B (en) 2010-07-28
US8143408B2 (en) 2012-03-27
EP2158198A4 (en) 2012-01-04
NZ581353A (en) 2012-02-24
US20120238579A1 (en) 2012-09-20
AU2008241610A1 (en) 2008-10-30
CA2685141A1 (en) 2008-10-30
SA08290245B1 (ar) 2012-02-12
MX2009011364A (es) 2009-11-05
EP2158198A2 (en) 2010-03-03
RU2009138137A (ru) 2011-05-27
US20100137322A1 (en) 2010-06-03
TW200848037A (en) 2008-12-16
CN101687860B (zh) 2012-07-04
UY31046A1 (es) 2008-11-28
ECSP099706A (es) 2009-11-30
CL2008001170A1 (es) 2009-05-22
WO2008130320A3 (en) 2008-12-18
KR20100015827A (ko) 2010-02-12
CN101687860A (zh) 2010-03-31
PE20090727A1 (es) 2009-07-23
BRPI0810354A2 (pt) 2014-10-21
JP2010525056A (ja) 2010-07-22
WO2008130320A2 (en) 2008-10-30
CO6251361A2 (es) 2011-02-21
AU2008241610B2 (en) 2011-08-18
IL201309A0 (en) 2010-05-31
EP2158198B1 (en) 2013-03-20
RU2460730C2 (ru) 2012-09-10
MY146662A (en) 2012-09-14

Similar Documents

Publication Publication Date Title
AR066266A1 (es) DERIVADOS DE CROMENO Y DE TETRAHIDRONAFTALENO uTILES PARA EL TRATAMIENTO DEL DOLOR
CN102686581B (zh) 喹唑啉衍生物
JP5244095B2 (ja) 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
ES2438240T3 (es) Nuevos derivados de biaril benzoimidazol y composición farmacéutica que los comprenden
RU2403251C2 (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70
US10442778B2 (en) N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels
AR064505A1 (es) Derivados ester o amida de imidazolilo, composiciones farmaceuticas que los comprenden,proceso de preparacion, y usos como medicamentos para el tratamiento de enfermedades inflamatorias, entre otras.
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
AR041467A1 (es) Indol-3-carboxamidas como activadores de glucoquinasa (gk)
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
PE20081806A1 (es) Imidazo- y triazolopirimidinas sustituidas
RU2015134558A (ru) Моноциклическое пиридиновое производное
JP2019536766A (ja) 2−置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途
ES2588835T3 (es) Compuestos de pirazol como inhibidores de SGLT1
CN102858177A (zh) 儿茶酚-o-甲基转移酶抑制剂及其在治疗精神障碍中的用途
RU2752163C2 (ru) Противоопухолевое средство и ингибитор бромодомена
JP2023002688A (ja) NotchシグナリングのエンハンサーならびにNotchのアップレギュレーションにより治療可能ながんおよび悪性腫瘍の治療におけるその使用
JP7530510B2 (ja) Rnaヘリカーゼdhx33を阻害する多環式化合物及びその応用
NZ593706A (en) Use of camptothecin-based compounds for sensitizing tumour cells to radiation
JP2016501869A (ja) α−(3,5−ジメトキシベンジリデン)−α’−炭化水素基メチレン環状ケトン
JP7681599B2 (ja) 選択的cdk4/6阻害剤のがん治療薬
AU2018215089B2 (en) Anti-fibrotic compounds
CN103006449B (zh) 酪氨酸酶抑制剂及其制备方法
JP5319457B2 (ja) 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
JP2018536652A5 (enExample)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal